Compare ARK Genomic Revolution ETF (ARKG) vs Deutsche Bank AG (DB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Deutsche Bank AG — how do they compare? ARK Genomic Revolution ETF trades at $41, while Deutsche Bank AG trades at $35.72 (market cap $68.30B). The key difference: Deutsche Bank AG pays a 3.25% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Deutsche Bank AG nearer its low. Which is the better fit depends on your goals.
| ARKG | DB | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $40.33 |
52-Week Low | $23.09 | $28.37 |
Market Cap | — | $68.30B |
Dividend Yield | — | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Deutsche Bank (DB) trades at $35.77, up 1.05% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamental momentum with Q1 2026 EPS beating expectations at $1.24 versus $1.15, and net income margin improving to 21.98% in 2025. Recent news includes expansion into Saudi Arabia and a dividend of $1.00 payable in June 2026, reflecting strategic growth initiatives.
Outlook is cautiously optimistic given low P/E of 9.94 and P/B of 0.77, suggesting undervaluation, but risks include volatile cash flows with a net outflow of $33.10B in 2024 and mixed analyst sentiment with only 21% buy ratings. Investors should weigh earnings consistency against macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
